José Ramón Santos

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain

Clara Suñer, María Ubals, Eloy José Tarín-Vicente et al. · The Lancet Infectious Diseases · 2022 · 168 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +13

Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV‐Infected Patients: Clinical Implications

Eugènia Negredo, Marta Massanella, Jordi Puig et al. · Clinical Infectious Diseases · 2010 · 152 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

José Ramón Santos, María Saumoy, Adrián Curran et al. · Clinical Infectious Diseases · 2015 · 140 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +5

Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study

Lourdes Mateu, Cristian Tebé, Cora Loste et al. · The Lancet Regional Health - Europe · 2023 · 113 citations · Full text

Nursing, Clinical Sciences, Clinical Epidemiology +16